Rempex Pharmaceuticals Inc.

Paediatric Infectious Disease

Clinical research in complicated urinary tract infection and acute pyelonephritis in children, with attention to infections affecting the urinary tract and kidney.

  • Complicated urinary tract infection
  • Acute pyelonephritis
  • Childhood bacterial infection

The sponsor’s research interest is centered on paediatric patients from infancy through early childhood, reflecting a focus on serious urinary tract infections in younger populations.

Anti-Infective Therapy

Work in antibacterial treatment for difficult urinary tract infections, including infections associated with upper urinary tract involvement.

  • Antibacterial therapy
  • Urinary tract infection management
  • Renal infection

Interest extends to treatment settings where infection control is important in hospital-based and specialist paediatric care environments.

Intravenous Treatment

Clinical activity includes intravenous infusion of an antibacterial regimen, with emphasis on treatment delivery in children who require parenteral therapy.

  • Intravenous infusion
  • Parenteral administration
  • Systemic antibacterial treatment

This area reflects interest in therapies used when oral options are not suitable and more direct systemic treatment is needed.

Pharmacokinetics and Safety

Research attention includes safety, tolerability, and pharmacokinetics in the paediatric setting, supporting evaluation of how treatment behaves in younger patients.

  • Safety assessment
  • Tolerability
  • Pharmacokinetic profile

These interests are relevant to the development of age-appropriate anti-infective therapies for children with serious bacterial infections.

Hospital Paediatrics

The sponsor’s clinical landscape includes care pathways for children treated across multiple research sites and countries, with focus on infections managed in specialised paediatric and acute care settings.

  • Specialised paediatric care
  • Acute infection management
  • Multisite clinical research

Research activity is concentrated on a narrow infectious disease area, with therapeutic interest in serious urinary tract infections requiring coordinated clinical evaluation.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of meropenem-vaborbactam safety and effectiveness in children aged 3 months to 12 years with complicated urinary tract infection or acute pyelonephritis

    Not recruiting

    1 1
    Investigated drugs:
    Belgium Bulgaria Croatia Greece Poland Spain